Skip to main content

Table 4 Overview of safety outcomes (Safety population)

From: A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer

Adverse events (AEs), n (%)

BTH1677/

Bevacizumab/

Carboplatin/Paclitaxel

(N = 59)

Bevacizumab/

Carboplatin/

Paclitaxel

(N = 30)

Any AE

58 (98.3)

30 (100.0)

NCI/CTCAE Grade 3 or 4 AEs

55 (93.2)

20 (66.7)

Serious AEs

24 (40.7)

13 (43.3)

BTH1677-related AEs

  

Probably related

13 (22.0)

NA

Possibly related

17 (28.8)

NA

AEs leading to discontinuation

21 (35.6)

12 (40.0)

  1. Abbreviations: AE adverse events, N overall sample size, n number of patients, NA not applicable, NCI/CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events
Back to article page